anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Children in the study aged 6 to 30 months followed or referred to CHIC for oral disorders will have a psychomotor assessment and a psychological interview. Questionnaires on eating behavior will also be proposed.
Participants will view a mock restaurant menu based on a popular US sit-down restaurant. They will be instructed to select the item or items they would like to order from the restaurant. The menu will display eco-labels next to more sustainable menu appetizers and entrees (i.e., appetizers and entrees that are in the bottom half of carbon footprints \[i.e., greenhouse gas emissions in CO2-equivalents associated with production of the item\] among appetizers and entrees).
The present invention refers to a crystalline antibacterial gel for hands with citric fragrance and moisturising properties, which is used by the public in general and mainly applied in places of frequent water shortage situations. The invention may be used daily and several times a day, and by children. The gel includes natural moisturising agents and a disinfecting antibacterial agent such as the pure cane ethylic alcohol. The composition of the present invention comprises different compounds, which upon being integrated provide more advantages than the gels currently available on the market, regarding the sensation, appearance and efficacy. The antibacterial gel composition consists of different compounds, which classified by their function comprise: a rheological modifier, sequestering agent, fragrance, an emulsifier, neutraliser, moisturiser, dissolvent and disinfectant. The manufacturing process of the composition comprises the performance of single operations currently used, w hich all together provide in a fast, effective and cost effective manner a gel with improved qualities in appearance, sensation and effectiveness. (FIG. 1).
Fibrosis is a common pathological process affecting multiple organs. It refers to an increase in fibrous connective tissue and a decrease in parenchymal cells in damaged tissues or organs. This may lead to structural damage and functional decline or even organ failure. The incidence of fibrosis is increasing worldwide, and the need for safe and effective therapeutic drugs and treatments is pivotal. The intestinal tract has a complex network of exchanging information with various tissues in the body. It contains a sizeable microbial community of which the homeostasis and metabolites are closely related to fibrosis. Polysaccharides are a class of biomolecules present in natural products; they have potential value as anti-fibrotic prebiotics. Recently, polysaccharides have been found to improve fibrosis in different organs by decreasing inflammation and modulating the immune function and intestinal microbiota. In this paper, we reviewed the progress made in research concerning polysaccharides and organ fibrosis in relation to the intestinal microbiota from the pathogenesis of fibrosis to the relationship between the intestinal flora and fibrosis. Furthermore, we provide ideas and references for future polysaccharide-drug discovery and strategies for the treatment of fibrosis.
At visit 1 and again at visit 2, participants assigned to the experimental arm will receive a 14-day supply of citicoline and omega-3 fatty acid, of which they will be instructed to take 1000 mg and 2000 mg daily, respectively. This will be done in a double-blind, randomized fashion.
This pilot study is a prospective study enrolling infants who are currently healthy, have no acute illness in preceding fourteen days, and were born full term that are presenting at FamilyCare - Children's Medicine Center (CMC) for their 2, 4, and 6-month well child visit that includes routine immunizations. Following informed consent, a blood sample will be obtained from enrolled infants for PCT testing prior to their routine, scheduled immunizations. The infants will return to CMC to have their PCT levels re-tested at 2 days post immunization. An infant will be included in the study for only one well child visit; if an infant presents for a subsequent well child visit falling within our sample visit age, the infant is not eligible for study re-enrollment. The parent/guardian will be contacted via telephone at week post second blood draw to determine if the infant has experienced symptoms or received medical care during that time period. The patient population targeted for this pilot study will be infants presenting to their pediatricians at FamilyCare - Children's Medicine Center for two, four, or six-month well child visits on a Monday, Tuesday, or Wednesday and receiving their vaccines as recommended by the 2014 CDC schedule.10 This is a pilot study, and therefore had no power analysis performed to calculate sample size. The investigators anticipate that there will be a high rate of patients not returning for the second blood draw, approximately 50%, based on prior patient experience of the investigators. To achieve the sample of at least 20 patients completing both blood draws and the phone interview, the investigators will enroll 45 patients.
PROBLEM TO BE SOLVED: To obtain a medicine composition containing heparin cofactor II (hereinafter referred to as HCII) as an active ingredient, and useful as a medicine for preventing and treating septicemia, abnormal blood flow-causing diseases, etc., and obtain a composition containing antitropin III (hereinafter referred to as ATIII). SOLUTION: This composition contains HCII as an active ingredient. The HCII is originated from a human, and purified in an extent capable of being used as a medicine. The natural HCII can be purified, e.g., from human whole blood, plasma, etc., and the artificial HCII is produced by culturing a host cell transformed with a recombined vector containing a DNA coding the natural HCII. The composition is preferably administered at a daily dose of 1-10000 unit/kg body. The composition is preferably administered together with the ATIII.
BACKGROUND/OBJECTIVES: Engineered nanomaterials (ENMs) have been suggested as being capable of promoting inflammation, a key component in the pathways associated with carcinogenesis, cardiovascular disease, and other conditions. As a result, the risk assessment of biological markers as early-stage indicators has the potential to improve translation from experimental toxicologic findings to identifying evidence in human studies. The study aims to review the possible early biological changes in workers exposed to carbon black (CB), followed by an evidentiary quality evaluation to determine the predictive value of the biological markers.
METHODS: We conducted a literature search to identify epidemiological studies that assessed biological markers that were involved in the inflammatory process at early stages among workers with exposure to CB. We reviewed the studies with specific reference to the study design, statistical analyses, findings, and limitations.
RESULTS: We identified five Chinese studies that investigated the potential impact of exposure to CB on inflammatory markers, bronchial wall thickening, genomic instability, and lung function impairment in CB production workers. Of the five Chinese studies, four were cross-sectional; another study reported results at two-time points over six years of follow-up. The authors of all five studies concluded positive relationships between exposure and the inflammatory cytokine profiles. The weak to very weak correlations between biomarkers and early-stage endpoints were reported.
CONCLUSION: Most inflammatory markers failed to satisfy the proposed evidentiary quality criteria. The significance of the results of the reviewed studies is limited by the cross-sectional study design, inconsistency in results, uncertain clinical relevance, and high occupational exposures. Based on this review, the risk assessment relying on inflammatory markers does not seem appropriate at this time. Nevertheless, the novel research warrants further exploration in assessing exposure to ENMs and corresponding potential health risks in occupational settings.
Adhering to Early Hearing Detection and Intervention (EHDI) guidelines is critical for the timely identification and management of infants with hearing impairment. Early intervention specifically focusses on family-centred communication interventions, of which the Listening and Spoken Language-South Africa (LSL-SA) approach is available for children with hearing impairment in South Africa. Studies have evidenced significant benefits for children with hearing impairment enrolled in LSL-SA compared to those enrolled in Traditional Speech-Language Therapy (TSLT), that is, age-equivalent communication outcomes, shorter duration of therapy until discharge, meritorious academic performance and integration into a hearing society. Despite these positive outcomes related to the LSL-SA approach, significant contextual barriers hinder effective implementation nationwide.Contribution: The successful implementation of EHDI guidelines in South Africa hinges on overcoming barriers through tailored healthcare strategies and contextualised delivery. Adapting frameworks such as LSL-SA to fit the local context is crucial for advancing equitable access to EHDI services, positively impacting children with hearing impairment and their families. This article highlights the systemic challenges in South Africa in optimising resources by adopting linguistically appropriate and culturally responsive early intervention approaches to champion hearing healthcare initiatives. Effective collaboration among diverse stakeholders is essential for enhancing the uptake of EHDI guidelines and translating policy into impactful communication interventions. Implementing the core principles of the LSL-SA approach will not only ensure access to this specialised service for suitable candidates but may also alleviate specific barriers to EHDI implementation within TSLT approaches.
Percutaneous nephrolithotomy (PNL) is used to remove large and complex stones from the upper urinary tract. Intracorporeal lithotripsy is an integral part of PNL. Commercially available intracorporeal lithotripsy modalities include ultrasonic, pneumatic, and combined ultrasonic and pneumatic models. Each modality has its inherent advantages and disadvantages. Ultrasonic lithotrites are capable of fragmenting stones while concomitantly suctioning out fragments. Unfortunately some stones are hard enough to resist fragmentation from ultrasonic lithotripsy. Pneumatic lithotrites are able to fragment all stones regardless of hardness, but this modality is unable to suction out stone pieces at the same time fragmentation is occurring. The newest lithotrite which combines both ultrasonic and pneumatic components is capable of fragmenting any stone, but also has some inherent limitations. The handpiece of the lithotripsy device is somewhat cumbersome, the suction component can clog, and the device has overheated at the maximal settings (Kuo et al). Current intracorporeal lithotrites, while functional, can certainly be improved.

Recently, a novel dual probe design has been introduced by Cybersonics of Erie, PA. This dual probe intracorporeal lithotrite is called the Cyberwand and is composed of a fixed inner probe vibrating at an ultrasonic frequency with an outer probe vibrating at about 1,000 Hz. As this new design has the potential to revolutionalize intracorporeal lithotripsy, we intend to compare this novel technology to currently available lithotripsy technology in a randomized clinical trial.
This paper presented a national register for esophageal atresia (EA) started in January 2008. We report our experience about the conception of this database and its coordination. Data management and data quality are also detailed. In 2023, more than 2,500 patients with EA are included. Prevalence of EA in France was calculated at 1.8/10,000 live birth. Main clinical results are listed with scientific publications issued directly from the register.
Participants from both Arm 1 and Arm 2 will be surveyed every 2 months for alcohol consumption for 2 years following the Experimental phase. Interventions include Abstinence from Alcohol and Usual Drinking.
Prior administration of succinylcholine may enhance the neuromuscular blocking effect of vecuronium and its duration of action. If succinylcholine is used before vecuronium, the administration of vecuronium should be delayed until the succinylcholine effect shows signs of wearing off. With succinylcholine as the intubating agent, initial doses of 0.04 to 0.06 mg/kg of vecuronium may be administered to produce complete neuromuscular block with clinical duration of action of 25 to 30 minutes (see CLINICAL PHARMACOLOGY). 

The use of vecuronium before succinylcholine, in order to attenuate some of the side effects of succinylcholine, has not been sufficiently studied.

Other nondepolarizing neuromuscular blocking agents (pancuronium, d-tubocurarine, metocurine, and gallamine) act in the same fashion as does vecuronium; therefore, these drugs and vecuronium, may manifest an additive effect when used together. There are insufficient data to support concomitant use of vecuronium and other competitive muscle relaxants in the same patient.
The total daily doses will be of 3g. The dose selection and the frequency of dosing was based on the results of the phase 1/2 study demonstrating that 3g/day of AT-001 is capable of producing the maximum inhibition of the production of sorbitol (a pharmacodynamic biomarker of biological activity).
According to the present invention, a pharmaceutical composition for preventing or treating tuberculous pleural fibrosis includes phNOX4 inhibitor. Tuberculous pleurisy often causes pleural fibrosis which causes respiratory failure. NOX (NADPH oxidase) enzymes provide hemostasis and host defenses in lungs. However, the role of NOX4 signaling in tuberculous pleurisy is unknown. The present inventors have investigated the role of NOX4 signaling in tuberculous pleural fibrosis by using an in a vitro pleural epithelial cell experiment and a BCG pleural infection mouse model. The result of the study suggests that thermally treated and killed Mycobacterium tuberculosis in pleural mesothelial cells induces NOX4-ROS production and epithelial mesenchymal migration. TLR4 inhibitors, TAK-242 and losartan, reduced NOX4-ROS production and subsequent fibrosis. SiRNA NOX4 pretreatment in cultured pleural epithelial cells inhibited thermally treated and killed Mycobacterium tuberculosis-induced collagen-1 synthesis and epithelial mesenchymal migration. NOX4 mediates thermally treated and killed Mycobacterium tuberculosis-induced epithelial mesenchymal migration and reactive oxygen species production in cells through activation of ERK signaling. In the BCG-induced pleurisy model, a BCG + SiNOX4 group (SiNOX4 IV posttreatment after BCG) reduced inflammatory pleural cell recruitment, inflammatory cytokine release, and mesenchymal fibrosis compared to a BCG + SiCon group (SiCon IV posttreatment after BCG). The results indicate that NOX4-ERK-ROS regulates thermally treated and killed Mycobacterium tuberculosis-induced pleural fibrosis through TLR4 and AT1R. NOX4 may be a new therapeutic target in tuberculous pleural fibrosis.
Provided is a kit comprising a vaccine to the influenza virus. The vaccine can be an immunogenic composition that comprises an inactivated influenza virus. The immunogenic compositions elicits can include subtypes A and/or type B of the influenza virus. A container, such as a single dose pre-filled syringe of the vaccine is placed inside of the kit. Another component of the kit can include a CSR (Central Supply Room) wrap. Another component of the kit can include sterile gloves. Another component of the kit can include a bandage. Another component of the kit can include a disinfectant for topical application, such as an alcohol pad. Another component of the kit can include an instruction sheet.
PURPOSE: To provide an immunogen derived from the tumor cells treated to increase specific immunogenicity and an antitumor vaccine contg. the immunogen. CONSTITUTION: The modified tumor cells are prepd. by acting a crosslinking agent, 2',3'-nucleoside or nucleotide aldehyde, more preferably the compd. of the formula (R is H, mono-, di- or triphosphate; B is the nucleotide base selected from adenine, guanine, cytosine, thymine, uracil and inosine) on the tumor cells at and for the concn. (more adequately >=20 mM) and time sufficient for inducing the crosslinking of the protein in the plasma membrane of these cells and simultaneously applying an isostatic pressure of 1200 to 1400 atm. The immunogen capable of inducing an antitumor immunological reaction is derived from these cells.  Examples of the immunogen include the modified tumor whole cells, the plasma membranes obtainable therefrom and the protein type substances which are obtainable from the cells and membranes described above and substantially retain the capacity to induce the antitumor immunological reaction from the cells described above.
FIELD: medicine. SUBSTANCE: method involves administering a course of Diuciphonum in electrophoresis treatment being 12-15 procedures long. The first two procedures are carried out at 0.05 mA/mA/cm 2  and the following procedures are carried out at 0.1 mA/mA/cm 2  during 20 min. Two joints or two areas of skin induration are exposed to treatment during 20 min in one day. EFFECT: accelerated treatment course. 38 dwg
The present invention relates to the treatment of pancreatic cancer. In this study, the results of the inventors led them to highlight the non-explored but relevant pathway in the pancreatic cancer field, the Fatty Acid Oxidation (FAO) pathway. Interestingly, they found that the mitochondrial respiration of PDAC cells depends mostly on this pathway. Thus they hypothesized that inhibition of FAO could be an effective therapeutic strategy against PDAC. 10 Their data support the hypothesis that this metabolic pathway plays a crucial role in PDAC, as it has been reported in other types of cancer. Thus, the invention relates to an inhibitor of fatty acid oxidation (FAO) for use in the treatment of pancreatic cancer in a patient in need thereof.
Oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper 5 mg every 4 weeks and discontinue by 4 months. After breakfast, oral prednisolone will be administered as a morning dose (8-10 am).
Oxycodone hydrochloride tablets are intended for the management of moderate to severe pain in patients who require treatment with an oral opioid analgesic. The dose should be individually adjusted according to severity of pain, patient response and patient size. If the pain increases in severity, if analgesia is not adequate, or if tolerance occurs, a gradual increase in dosage may be required.

Patients who have not been receiving opioid analgesics should be started on oxycodone hydrochloride tablets in a dosing range of 5 to 15 mg every 4 to 6 hours as needed for pain. The dose should be titrated based upon the individual patient's response to their initial dose of oxycodone hydrochloride tablets. Patients with chronic pain should have their dosage given on an around-the-clock basis to prevent the reoccurrence of pain rather than treating the pain after it has occurred. This dose can then be adjusted to an acceptable level of analgesia taking into account side effects experienced by the patient.

For control of severe chronic pain, oxycodone hydrochloride tablets should be administered on a regularly scheduled basis, every 4 to 6 hours, at the lowest dosage level that will achieve adequate analgesia.

As with any potent opioid, it is critical to adjust the dosing regimen for each patient individually, taking into account the patient's prior analgesic treatment experience. Although it is not possible to list every condition that is important to the selection of the initial dose of oxycodone hydrochloride tablets, attention should be given to: 1) the daily dose, potency, and characteristics of a pure agonist or mixed agonist/antagonist the patient has been taking previously, 2) the reliability of the relative potency estimate to calculate the dose of oxycodone needed, 3) the degree of opioid tolerance, 4) the general condition and medical status of the patient, and 5) the balance between pain control and adverse experiences.
Participants will be recruited if they have Parkinson's disease, Parkinsonism. Inclusion and exclusion criteria are summarized below. Participants will be screened at the first visit to make sure they are eligible for the trial. They will then undergo baseline testing including neurologic evaluation, questions to assess their memory and cognitive status and evaluation of their disease status using parts of the Unified Parkinsons's Disease Ratings Scale (UPDRS) that are routinely used to follow disease progression. They will be given a questionnaire to evaluate the severity of their drooling. Their saliva production will be measured by having them spit into a cup for 5 minutes, twice.

At the first visit, after making sure they are eligible for the study and performing the baseline testing and procedures, they will be given either Xeomin or placebo (saline injections without medication) injections in the 4 glands that produce saliva. They will not know which injection they received. This visit will take about 2 hours. They will be followed up every month and asked about side effects, have neurologic evaluation and ALS-FRS testing and fill-in the questionnaire for drooling severity. Saliva volume will be measured as done at the first visit. At either Month 4 or 5, participants will receive the second injection. This will be a "cross-over" injection, i.e., if they received Xeomin at the first injection they will receive saline at the second and vice versa. Thus, all participants will receive the study medication Xeomin, either as the first injection or the second injection at 4 months or 5 months. The follow up after the second injection will be one monthly visit for 3 months, with similar evaluations as described above. The follow-up visit will take about 1 hour each.
INTRODUCTION: Neurobiological dysfunction is associated with depression in children and adolescents. While research in adult depression suggests that inflammation may underlie the association between depression and brain alterations, it is unclear if altered levels of inflammatory markers provoke neurobiological dysfunction in early-onset depression. The aim of this scoping review was to provide an overview of existing literature investigating the potential interaction between neurobiological function and inflammation in depressed children and adolescents.
METHODS: Systematic searches were conducted in six databases. Primary research studies that included measures of both neurobiological functioning and inflammation among children (≤18 years) with a diagnosis of depression were included.
RESULTS: Four studies (240 participants; mean age 16.0 ± 0.6 years, 62% female) meeting inclusion criteria were identified. Studies primarily examined the inflammatory markers interleukin 6, tumor necrosis factor alpha, C-reactive protein, and interleukin 1 beta. Exploratory whole brain imaging and analysis as well as region of interest approaches focused on the anterior cingulate cortex, basal ganglia, and white matter tracts were conducted. Most studies found correlations between neurobiological function and inflammatory markers; however, depressive symptoms were not observed to moderate these effects.
CONCLUSIONS: A small number of highly heterogeneous studies indicate that depression may not modulate the association between altered inflammation and neurobiological dysfunction in children and adolescents. Replication in larger samples using consistent methodological approaches (focus on specific inflammatory markers, examine certain brain areas) is needed to advance the knowledge of potential neuro-immune interactions early in the course of depression.